000103222009/302025Q3FALSEP3YP1Yxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesmms:segmentxbrli:puremms:agreement00010322202024-10-012025-06-3000010322202025-08-0400010322202025-04-012025-06-3000010322202024-04-012024-06-3000010322202023-10-012024-06-3000010322202025-06-3000010322202024-09-3000010322202023-09-3000010322202024-06-300001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-09-300001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001032220us-gaap:RetainedEarningsMember2024-09-300001032220us-gaap:RetainedEarningsMember2024-10-012024-12-3100010322202024-10-012024-12-310001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-012024-12-310001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-10-012024-12-310001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-12-310001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001032220us-gaap:RetainedEarningsMember2024-12-3100010322202024-12-310001032220us-gaap:RetainedEarningsMember2025-01-012025-03-3100010322202025-01-012025-03-310001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-01-012025-03-310001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-03-310001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001032220us-gaap:RetainedEarningsMember2025-03-3100010322202025-03-310001032220us-gaap:RetainedEarningsMember2025-04-012025-06-300001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-04-012025-06-300001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2025-06-300001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001032220us-gaap:RetainedEarningsMember2025-06-300001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-09-300001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001032220us-gaap:RetainedEarningsMember2023-09-300001032220us-gaap:RetainedEarningsMember2023-10-012023-12-3100010322202023-10-012023-12-310001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-012023-12-310001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-10-012023-12-310001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2023-12-310001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001032220us-gaap:RetainedEarningsMember2023-12-3100010322202023-12-310001032220us-gaap:RetainedEarningsMember2024-01-012024-03-3100010322202024-01-012024-03-310001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-01-012024-03-310001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-03-310001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001032220us-gaap:RetainedEarningsMember2024-03-3100010322202024-03-310001032220us-gaap:RetainedEarningsMember2024-04-012024-06-300001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-04-012024-06-300001032220us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember2024-06-300001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001032220us-gaap:RetainedEarningsMember2024-06-300001032220us-gaap:TechnologyEquipmentMember2025-06-300001032220us-gaap:OperatingSegmentsMembermms:U.S.FederalServicesMember2025-04-012025-06-300001032220us-gaap:OperatingSegmentsMembermms:U.S.FederalServicesMember2024-04-012024-06-300001032220us-gaap:OperatingSegmentsMembermms:U.S.FederalServicesMember2024-10-012025-06-300001032220us-gaap:OperatingSegmentsMembermms:U.S.FederalServicesMember2023-10-012024-06-300001032220us-gaap:OperatingSegmentsMembermms:USServicesMember2025-04-012025-06-300001032220us-gaap:OperatingSegmentsMembermms:USServicesMember2024-04-012024-06-300001032220us-gaap:OperatingSegmentsMembermms:USServicesMember2024-10-012025-06-300001032220us-gaap:OperatingSegmentsMembermms:USServicesMember2023-10-012024-06-300001032220us-gaap:OperatingSegmentsMembermms:OutsideTheUnitedStatesMember2025-04-012025-06-300001032220us-gaap:OperatingSegmentsMembermms:OutsideTheUnitedStatesMember2024-04-012024-06-300001032220us-gaap:OperatingSegmentsMembermms:OutsideTheUnitedStatesMember2024-10-012025-06-300001032220us-gaap:OperatingSegmentsMembermms:OutsideTheUnitedStatesMember2023-10-012024-06-300001032220us-gaap:MaterialReconcilingItemsMember2025-04-012025-06-300001032220us-gaap:MaterialReconcilingItemsMember2024-04-012024-06-300001032220us-gaap:MaterialReconcilingItemsMember2024-10-012025-06-300001032220us-gaap:MaterialReconcilingItemsMember2023-10-012024-06-300001032220mms:ProgramOperationsMember2025-04-012025-06-300001032220mms:ProgramOperationsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220mms:ProgramOperationsMember2024-04-012024-06-300001032220mms:ProgramOperationsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220mms:ProgramOperationsMember2024-10-012025-06-300001032220mms:ProgramOperationsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220mms:ProgramOperationsMember2023-10-012024-06-300001032220mms:ProgramOperationsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220mms:ClinicalServicesMember2025-04-012025-06-300001032220mms:ClinicalServicesMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220mms:ClinicalServicesMember2024-04-012024-06-300001032220mms:ClinicalServicesMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220mms:ClinicalServicesMember2024-10-012025-06-300001032220mms:ClinicalServicesMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220mms:ClinicalServicesMember2023-10-012024-06-300001032220mms:ClinicalServicesMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220mms:EmploymentAndOtherMember2025-04-012025-06-300001032220mms:EmploymentAndOtherMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220mms:EmploymentAndOtherMember2024-04-012024-06-300001032220mms:EmploymentAndOtherMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220mms:EmploymentAndOtherMember2024-10-012025-06-300001032220mms:EmploymentAndOtherMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220mms:EmploymentAndOtherMember2023-10-012024-06-300001032220mms:EmploymentAndOtherMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220mms:TechnologySolutionsMember2025-04-012025-06-300001032220mms:TechnologySolutionsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220mms:TechnologySolutionsMember2024-04-012024-06-300001032220mms:TechnologySolutionsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220mms:TechnologySolutionsMember2024-10-012025-06-300001032220mms:TechnologySolutionsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220mms:TechnologySolutionsMember2023-10-012024-06-300001032220mms:TechnologySolutionsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220mms:PerformanceBasedContractsMember2025-04-012025-06-300001032220mms:PerformanceBasedContractsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220mms:PerformanceBasedContractsMember2024-04-012024-06-300001032220mms:PerformanceBasedContractsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220mms:PerformanceBasedContractsMember2024-10-012025-06-300001032220mms:PerformanceBasedContractsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220mms:PerformanceBasedContractsMember2023-10-012024-06-300001032220mms:PerformanceBasedContractsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220mms:CostPlusContractsMember2025-04-012025-06-300001032220mms:CostPlusContractsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220mms:CostPlusContractsMember2024-04-012024-06-300001032220mms:CostPlusContractsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220mms:CostPlusContractsMember2024-10-012025-06-300001032220mms:CostPlusContractsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220mms:CostPlusContractsMember2023-10-012024-06-300001032220mms:CostPlusContractsMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220us-gaap:FixedPriceContractMember2025-04-012025-06-300001032220us-gaap:FixedPriceContractMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220us-gaap:FixedPriceContractMember2024-04-012024-06-300001032220us-gaap:FixedPriceContractMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220us-gaap:FixedPriceContractMember2024-10-012025-06-300001032220us-gaap:FixedPriceContractMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220us-gaap:FixedPriceContractMember2023-10-012024-06-300001032220us-gaap:FixedPriceContractMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220us-gaap:TimeAndMaterialsContractMember2025-04-012025-06-300001032220us-gaap:TimeAndMaterialsContractMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220us-gaap:TimeAndMaterialsContractMember2024-04-012024-06-300001032220us-gaap:TimeAndMaterialsContractMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220us-gaap:TimeAndMaterialsContractMember2024-10-012025-06-300001032220us-gaap:TimeAndMaterialsContractMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220us-gaap:TimeAndMaterialsContractMember2023-10-012024-06-300001032220us-gaap:TimeAndMaterialsContractMembermms:ContractConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220mms:NewYorkStateGovernmentAgenciesMember2025-04-012025-06-300001032220mms:NewYorkStateGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220mms:NewYorkStateGovernmentAgenciesMember2024-04-012024-06-300001032220mms:NewYorkStateGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220mms:NewYorkStateGovernmentAgenciesMember2024-10-012025-06-300001032220mms:NewYorkStateGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220mms:NewYorkStateGovernmentAgenciesMember2023-10-012024-06-300001032220mms:NewYorkStateGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220mms:OtherUnitedStateGovernmentAgenciesMember2025-04-012025-06-300001032220mms:OtherUnitedStateGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220mms:OtherUnitedStateGovernmentAgenciesMember2024-04-012024-06-300001032220mms:OtherUnitedStateGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220mms:OtherUnitedStateGovernmentAgenciesMember2024-10-012025-06-300001032220mms:OtherUnitedStateGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220mms:OtherUnitedStateGovernmentAgenciesMember2023-10-012024-06-300001032220mms:OtherUnitedStateGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220mms:TotalUnitedStatesStateGovernmentAgenciesMember2025-04-012025-06-300001032220mms:TotalUnitedStatesStateGovernmentAgenciesMember2024-04-012024-06-300001032220mms:TotalUnitedStatesStateGovernmentAgenciesMember2024-10-012025-06-300001032220mms:TotalUnitedStatesStateGovernmentAgenciesMember2023-10-012024-06-300001032220mms:UnitedStatesFederalGovernmentAgenciesMember2025-04-012025-06-300001032220mms:UnitedStatesFederalGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220mms:UnitedStatesFederalGovernmentAgenciesMember2024-04-012024-06-300001032220mms:UnitedStatesFederalGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220mms:UnitedStatesFederalGovernmentAgenciesMember2024-10-012025-06-300001032220mms:UnitedStatesFederalGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220mms:UnitedStatesFederalGovernmentAgenciesMember2023-10-012024-06-300001032220mms:UnitedStatesFederalGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220mms:InternationalGovernmentAgenciesMember2025-04-012025-06-300001032220mms:InternationalGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220mms:InternationalGovernmentAgenciesMember2024-04-012024-06-300001032220mms:InternationalGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220mms:InternationalGovernmentAgenciesMember2024-10-012025-06-300001032220mms:InternationalGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220mms:InternationalGovernmentAgenciesMember2023-10-012024-06-300001032220mms:InternationalGovernmentAgenciesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220mms:OtherIncludingLocalMunicipalitiesAndCommercialCustomersMember2025-04-012025-06-300001032220mms:OtherIncludingLocalMunicipalitiesAndCommercialCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2025-04-012025-06-300001032220mms:OtherIncludingLocalMunicipalitiesAndCommercialCustomersMember2024-04-012024-06-300001032220mms:OtherIncludingLocalMunicipalitiesAndCommercialCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-06-300001032220mms:OtherIncludingLocalMunicipalitiesAndCommercialCustomersMember2024-10-012025-06-300001032220mms:OtherIncludingLocalMunicipalitiesAndCommercialCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-10-012025-06-300001032220mms:OtherIncludingLocalMunicipalitiesAndCommercialCustomersMember2023-10-012024-06-300001032220mms:OtherIncludingLocalMunicipalitiesAndCommercialCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-10-012024-06-300001032220us-gaap:UnbilledRevenuesMember2025-06-300001032220us-gaap:UnbilledRevenuesMember2024-09-300001032220us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember2025-04-012025-06-300001032220us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember2024-04-012024-06-300001032220us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember2024-10-012025-06-300001032220us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember2023-10-012024-06-3000010322202025-07-012025-06-300001032220us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermms:BusinessesInAustraliaAndKoreaMember2024-12-012024-12-310001032220us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermms:BusinessesInAustraliaAndKoreaMember2025-06-300001032220us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermms:BusinessesInItalyAndSingaporeAndEmploymentServicesInCanadaMember2023-11-012023-11-300001032220mms:TermLoanADue2029Memberus-gaap:SecuredDebtMember2025-06-300001032220mms:TermLoanADue2029Memberus-gaap:SecuredDebtMember2024-09-300001032220mms:TermLoanBDue2031Memberus-gaap:SecuredDebtMember2025-06-300001032220mms:TermLoanBDue2031Memberus-gaap:SecuredDebtMember2024-09-300001032220us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2025-06-300001032220us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-09-300001032220mms:SubsidiaryLoansMember2025-06-300001032220mms:SubsidiaryLoansMember2024-09-300001032220mms:TermLoanADue2029Memberus-gaap:SecuredDebtMember2025-03-202025-03-200001032220us-gaap:InterestRateSwapMembermms:TermLoanBDueSeptember2025Memberus-gaap:SecuredDebtMember2025-06-300001032220us-gaap:InterestRateSwapMembermms:TermLoanADueMay2026Memberus-gaap:SecuredDebtMember2025-06-300001032220us-gaap:InterestRateSwapMembermms:TermLoanBDueSeptember2026Memberus-gaap:SecuredDebtMember2025-06-300001032220us-gaap:InterestRateSwapMembermms:TermLoanADueSeptember2027Memberus-gaap:SecuredDebtMember2025-06-300001032220us-gaap:InterestRateSwapMembermms:TermLoanADueSeptember2028Memberus-gaap:SecuredDebtMember2025-06-300001032220us-gaap:OtherAssetsMember2025-06-300001032220us-gaap:OtherLiabilitiesMember2025-06-300001032220us-gaap:OtherAssetsMember2024-09-300001032220us-gaap:OtherLiabilitiesMember2024-09-300001032220us-gaap:InterestRateSwapMemberus-gaap:SubsequentEventMember2025-07-012025-07-310001032220us-gaap:InterestRateSwapMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2025-07-310001032220us-gaap:InterestRateSwapMembermms:TermLoanADueSeptember2028Memberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2025-07-310001032220us-gaap:InterestRateSwapMembermms:TermLoanADueSeptember2027Memberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2025-07-310001032220us-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-06-300001032220us-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-06-300001032220us-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-06-300001032220us-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2025-06-300001032220us-gaap:InterestRateSwapMember2025-06-300001032220us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-06-300001032220us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-06-300001032220us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-06-300001032220us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2025-06-300001032220us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-06-300001032220us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-06-300001032220us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2025-06-300001032220us-gaap:FairValueMeasurementsRecurringMember2025-06-300001032220us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300001032220us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-09-300001032220us-gaap:AccumulatedTranslationAdjustmentMember2024-10-012025-06-300001032220us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-10-012025-06-300001032220us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-012025-06-300001032220us-gaap:AccumulatedTranslationAdjustmentMember2025-06-300001032220us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-06-300001032220us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMembermms:EmployeeMember2024-10-012025-06-300001032220us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMembermms:EmployeeMember2024-10-012025-06-300001032220srt:DirectorMemberus-gaap:RestrictedStockUnitsRSUMember2024-10-012025-06-300001032220srt:MinimumMemberus-gaap:PerformanceSharesMember2024-10-012025-06-300001032220srt:MaximumMemberus-gaap:PerformanceSharesMember2024-10-012025-06-300001032220us-gaap:PerformanceSharesMember2024-10-012025-06-300001032220us-gaap:RestrictedStockUnitsRSUMember2024-10-012025-06-300001032220srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2024-10-012025-06-300001032220srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2024-10-012025-06-300001032220mms:June2024ResolutionAdoptionsMember2025-06-300001032220mms:December2024ResolutionAdoptionsMember2025-06-300001032220us-gaap:BilledRevenuesMember2025-06-300001032220us-gaap:BilledRevenuesMember2024-09-3000010322202022-09-210001032220us-gaap:SubsequentEventMember2025-07-052025-07-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark one)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________to__________.

Commission file number: 1-12997


Maximus, Inc.
(Exact name of registrant as specified in its charter)

Virginia						54-1000588
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

1600 Tysons Boulevard, McLean, Virginia						22102
(Address of principal executive offices)						(Zip Code)

(703) 251-8500
(Registrant's telephone number, including the area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, no par value

MMS

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

There were 56,349,629 shares of the registrant's Common Stock outstanding as of August 4, 2025.

Table of Contents

Table of Contents to Third Quarter 2025 Form 10-Q


	SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS	3
Part I - Financial Information		5
Item 1.	Financial Statements	5
	Consolidated Statements of Operations	5
	Consolidated Statements of Comprehensive Income	6
	Consolidated Balance Sheets	7
	Consolidated Statements of Cash Flows	8
	Consolidated Statements of Changes in Shareholders’ Equity	9
	Notes to Consolidated Financial Statements	11
	1. Organization	11
	2. Significant Accounting Policies	11
	3. Business Segments	12
	4. Revenue Recognition	14
	5. Earnings Per Share	16
	6. Divestitures	16
	7. Debt and Derivatives	17
	8. Fair Value Measurements	18
	9. Equity	19
	10. Other Items	20
	11. Commitments and Contingencies	21
	12. Subsequent Event	22
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	23
	Business Overview	23
	Financial Overview	24
	Results of Operations	24
	Liquidity and Capital Resources	29
	Critical Accounting Policies and Estimates	32
	Non-GAAP and Other Measures	32
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	34
Item 4.	Controls and Procedures	34
Part II - Other Information		35
Item 1.	Legal Proceedings	35
Item 1A.	Risk Factors	35
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	35
Item 3.	Defaults Upon Senior Securities	35
Item 4.	Mine Safety Disclosures	35
Item 5.	Other Information	35
Item 6.	Exhibits	36
	Signatures	37

Table of Contents

Unless otherwise specified, references in this Quarterly Report on Form 10-Q to "our," "we," "us," "Maximus," the "Company," and "our business" refer to Maximus, Inc. and its subsidiaries.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Included in this Quarterly Report on Form 10-Q are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "opportunity," "could," "potential," "believe," "project," "estimate," "expect," "continue," "forecast," "strategy," "future," "likely," "may," "should," "will," and similar references to future periods.

Any statements herein that are not historical facts, including statements about our confidence, strategies and initiatives, and our expectations about revenues, results of operations, profitability, liquidity, market demand, and our recent acquisitions and divestitures, are forward-looking statements that are subject to risks and uncertainties. These risks could cause our actual results to differ materially from those indicated by such forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

•a failure to meet performance requirements under our contracts could lead to penalties, liquidated damages, actual damages, adverse settlement agreements, and/or contract termination;

•our ability to successfully compete, bid for, and accurately price contracts to generate our desired profit;

•the effects of future legislative or government budgetary and spending changes;

•the impact of the U.S. government on federal procurement, federal funding to states' safety-net programs, and the overall decision-making process related to our industry, including our business and customers;

•the ability of the U.S. government to issue or revise existing rules, regulations, executive orders, and directives at any time, or to take non-routine actions, which creates uncertainty for our business operations and requires significant additional compliance efforts and costs;

•our ability to manage our growth, including acquired businesses;

•difficulties in integrating or achieving projected revenues, earnings, and other benefits associated with acquired businesses;

•the outcome of reviews or audits, which might result in financial penalties and impair our ability to respond to invitations for new work;

•our ability to manage capital investments and other contract startup costs;

•our ability to manage our debt;

•our ability to maintain our technology systems and otherwise protect confidential or protected information;

•our discovery of additional information related to our previously disclosed cybersecurity incident and any potential legal, business, reputational, or financial consequences resulting from that incident;

•our ability to attract and retain executive officers, senior managers, and other qualified personnel to execute our business;

•the effect of union activity and organizing efforts at our U.S. locations;

•the ability of government customers to not exercise options, or to recompete or terminate contracts on short notice, with or without cause;

•our ability to win recompetes and/or succeed in protests on our significant contracts;

•our reliance on a small number of individual contracts;

•our ability to realize the full value of our backlog;

•our ability to maintain relationships with key government entities from whom a substantial portion of our revenue is derived;

•a failure to comply with laws governing our business, which might result in the Company being subject to fines, penalties, suspension, debarment, and other sanctions;

•the costs and outcome of litigation;

•our ability to manage third parties upon whom we depend to provide services to our customers;

•the effects of changes in laws and regulations governing our business, including actions resulting from non-routine government actions or orders, changes in tax laws and applicable interpretations and guidance thereunder, or changes in accounting policies, rules, methodologies, and practices, and our ability to estimate the impact of such changes, including shifting macroeconomic conditions and uncertainty;

•the effects of emerging technologies, such as artificial intelligence (AI) and machine learning (ML), on our business;

Table of Contents

•matters related to businesses we disposed of or divested; and

•other factors set forth in Item 1A, "Risk Factors" of our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on November 21, 2024 (2024 Form 10-K) as supplemented by the risk factor set forth in Part II, Item 1A, "Risk Factors" in our Quarterly Report on Form 10-Q filed with the SEC on May 8, 2025 (2025 Q2 10-Q).

Any forward-looking statement made by us in this report is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.

Table of Contents

PART I - Financial Information

Item 1. Financial Statements

Maximus, Inc.

Consolidated Statements of Operations

(Unaudited)


	For the Three Months Ended				For the Nine Months Ended
	June 30, 2025		June 30, 2024		June 30, 2025		June 30, 2024
	(in thousands, except per share amounts)
Revenue	$	1,348,400	$	1,314,929	$	4,112,861	$	3,990,327
Cost of revenue	988,887		982,615		3,112,970		3,040,370
Gross profit	359,513		332,314		999,891		949,957
Selling, general, and administrative expenses	170,831		167,033		525,423		504,682
Amortization of intangible assets	23,010		23,542		69,041		68,532
Operating income	165,672		141,739		405,427		376,743
Interest expense	22,657		20,555		61,648		62,428
Other expense/(income), net	48		809		(603)		475
Income before income taxes	142,967		120,375		344,382		313,840
Provision for income taxes	36,986		30,623		100,636		79,430
Net income	$	105,981	$	89,752	$	243,746	$	234,410

Earnings per share:
Basic	$	1.87	$	1.47	$	4.22	$	3.83
Diluted	$	1.86	$	1.46	$	4.20	$	3.81
Weighted average shares outstanding:
Basic	56,683		61,079		57,776		61,233
Diluted	56,984		61,381		58,100		61,495

Dividends declared per share	$	0.30	$	0.30	$	0.90	$	0.90

See accompanying notes to consolidated financial statements.

Table of Contents

Maximus, Inc.

Consolidated Statements of Comprehensive Income

(Unaudited)


	For the Three Months Ended				For the Nine Months Ended
	June 30, 2025		June 30, 2024		June 30, 2025		June 30, 2024
	(in thousands)
Net income	$	105,981	$	89,752	$	243,746	$	234,410
Other comprehensive income, net of tax:
Foreign currency translation adjustments	7,320		412		21,503		4,079
Net losses on cash flow hedges, net of tax benefit of $561, $427, $596, and $2,639, respectively	(1,574)		(1,197)		(1,672)		(7,398)
Other comprehensive income/(loss)	5,746		(785)		19,831		(3,319)
Comprehensive income	$	111,727	$	88,967	$	263,577	$	231,091

See accompanying notes to consolidated financial statements.

Table of Contents

Maximus, Inc.

Consolidated Balance Sheets


	June 30, 2025		September 30, 2024
	(unaudited)
	(in thousands)
Assets:
Cash and cash equivalents	$	59,777	$	183,123
Accounts receivable, net	1,422,350		879,514
Income taxes receivable	5,661		5,282
Prepaid expenses and other current assets	117,243		132,625
Total current assets	1,605,031		1,200,544
Property and equipment, net	34,536		38,977
Capitalized software, net	217,433		187,677
Operating lease right-of-use assets	115,437		133,594
Goodwill	1,782,836		1,782,871
Intangible assets, net	561,566		630,569
Deferred contract costs, net	60,392		59,432
Deferred compensation plan assets	58,714		55,913
Deferred income taxes	11,059		14,801
Other assets	15,289		27,130
Total assets	$	4,462,293	$	4,131,508
Liabilities and Shareholders' Equity:
Liabilities:
Accounts payable and accrued liabilities	$	281,994	$	303,321
Accrued compensation and benefits	164,194		237,121
Deferred revenue, current portion	70,197		83,238
Income taxes payable	31,310		26,535
Long-term debt, current portion	48,263		40,139
Operating lease liabilities, current portion	39,882		47,656
Other current liabilities	70,311		69,519
Total current liabilities	706,151		807,529
Deferred revenue, non-current portion	48,990		45,077
Deferred income taxes	161,426		169,118
Long-term debt, non-current portion	1,608,982		1,091,954
Deferred compensation plan liabilities, non-current portion	58,736		57,599
Operating lease liabilities, non-current portion	83,390		97,221
Other liabilities	21,582		20,195
Total liabilities	2,689,257		2,288,693
Commitments and contingencies (Note 11)
Shareholders' equity:
Common stock, no par value; 100,000 shares authorized; 56,350 and 60,352 shares issued and outstanding as of June 30, 2025 and September 30, 2024, respectively	627,496		598,304
Accumulated other comprehensive loss	(12,629)		(32,460)
Retained earnings	1,158,169		1,276,971
Total shareholders' equity	1,773,036		1,842,815
Total liabilities and shareholders' equity	$	4,462,293	$	4,131,508

See accompanying notes to consolidated financial statements.

Table of Contents

Maximus, Inc.

Consolidated Statements of Cash Flows

(Unaudited)


	For the Nine Months Ended
	June 30, 2025		June 30, 2024
	(in thousands)
Cash flows from operating activities:
Net income	$	243,746	$	234,410
Adjustments to reconcile net income to cash flows from operations:
Depreciation and amortization of property, equipment, and capitalized software	27,502		24,146
Amortization of intangible assets	69,041		68,532
Amortization of debt issuance costs and debt discount	2,046		2,899


Deferred income taxes	(5,829)		(3,770)
Stock compensation expense	30,324		27,605
Divestiture-related charges	39,343		1,018
Change in assets and liabilities, net of effects of business combinations and divestitures:
Accounts receivable	(553,297)		(26,528)
Prepaid expenses and other current assets	9,341		19,316
Deferred contract costs	(856)		(8,377)
Accounts payable and accrued liabilities	(21,808)		(1,659)
Accrued compensation and benefits	(50,369)		(21,043)
Deferred revenue	(8,675)		18,079
Income taxes	5,625		10,576
Operating lease right-of-use assets and liabilities	(3,508)		(2,131)

Other assets and liabilities	(2,626)		8,351
Net cash (used in)/provided by operating activities	(220,000)		351,424
Cash flows from investing activities:
Purchases of property and equipment and capitalized software	(55,686)		(82,237)
Asset acquisition	—		(18,006)
Proceeds from divestitures	736		3,078
Other	(2,165)		—
Net cash used in investing activities	(57,115)		(97,165)
Cash flows from financing activities:
Cash dividends paid to Maximus shareholders	(51,865)		(54,847)
Purchases of Maximus common stock	(306,443)		(47,275)
Tax withholding related to RSU vesting	(16,451)		(13,455)
Payments for contingent consideration	—		(10,977)
Payments for debt financing costs	(1,658)		(9,724)
Proceeds from borrowings	1,335,208		850,166
Principal payments for debt	(810,174)		(952,825)
Other	(1,824)		9,118
Net cash provided by/(used in) financing activities	146,793		(229,819)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(65)		1,270
Net change in cash, cash equivalents, and restricted cash	(130,387)		25,710
Cash, cash equivalents, and restricted cash, beginning of period	235,763		122,091
Cash, cash equivalents, and restricted cash, end of period	$	105,376	$	147,801

See accompanying notes to consolidated financial statements.

Table of Contents

Maximus, Inc.

Consolidated Statements of Changes in Shareholders' Equity

(Unaudited)


	Common Stock			Accumulated Other Comprehensive Loss		Retained Earnings		Total Equity
	Shares	Amount
	(in thousands)
Balance at September 30, 2024	60,352	$	598,304	$	(32,460)	$	1,276,971	$	1,842,815
Net income	—	—		—		41,196		41,196
Foreign currency translation	—	—		10,452		—		10,452
Cash flow hedge, net of tax	—	—		2,454		—		2,454
Cash dividends	—	—		—		(18,060)		(18,060)
Dividends on RSUs	—	301		—		(301)		—
Purchases of Maximus common stock	(3,113)	—		—		(236,655)		(236,655)
Stock compensation expense	—	6,952		—		—		6,952
Tax withholding adjustment related to RSU vesting	—	(2,305)		—		—		(2,305)
RSUs vested	47	—		—		—		—
Balance as of December 31, 2024	57,286	603,252		(19,554)		1,063,151		1,646,849
Net income	—	—		—		96,569		96,569
Foreign currency translation	—	—		3,731		—		3,731
Cash flow hedge, net of tax	—	—		(2,552)		—		(2,552)
Cash dividends	—	—		—		(16,901)		(16,901)
Dividends on RSUs	—	440		—		(440)		—
Purchases of Maximus common stock	(947)	—		—		(72,845)		(72,845)
Stock compensation expense	—	12,623		—		—		12,623

RSUs vested	10	—		—		—		—
Balance as of March 31, 2025	56,349	616,315		(18,375)		1,069,534		1,667,474
Net income	—	—		—		105,981		105,981
Foreign currency translation	—	—		7,320		—		7,320
Cash flow hedge, net of tax	—	—		(1,574)		—		(1,574)
Cash dividends	—	—		—		(16,904)		(16,904)
Dividends on RSUs	—	442		—		(442)		—

Stock compensation expense	—	10,749		—		—		10,749
Tax withholding adjustment related to RSU vesting	—	(10)		—		—		(10)
RSUs vested	1	—		—		—		—
Balance as of June 30, 2025	56,350	$	627,496	$	(12,629)	$	1,158,169	$	1,773,036

See accompanying notes to consolidated financial statements.

Table of Contents

Maximus, Inc.

Consolidated Statements of Changes in Shareholders' Equity

(Unaudited)


	Common Stock			Accumulated Other Comprehensive Loss		Retained Earnings		Total Equity
	Shares	Amount
	(in thousands)
Balance at September 30, 2023	60,998	$	577,898	$	(27,615)	$	1,117,552	$	1,667,835
Net income	—	—		—		64,148		64,148
Foreign currency translation	—	—		5,912		—		5,912
Cash flow hedge, net of tax	—	—		(8,885)		—		(8,885)
Cash dividends	—	—		—		(18,299)		(18,299)
Dividends on RSUs	—	285		—		(285)		—

Stock compensation expense	—	9,427		—		—		9,427
Tax withholding adjustment related to RSU vesting	—	(2,332)		—		—		(2,332)
RSUs vested	33	—		—		—		—
Balance as of December 31, 2023	61,031	585,278		(30,588)		1,163,116		1,717,806
Net income	—	—		—		80,510		80,510
Foreign currency translation	—	—		(2,245)		—		(2,245)
Cash flow hedge, net of tax	—	—		2,684		—		2,684
Cash dividends	—	—		—		(18,309)		(18,309)
Dividends on RSUs	—	412		—		(412)		—

Stock compensation expense	—	8,697		—		—		8,697

RSUs vested	6	—		—		—		—
Balance as of March 31, 2024	61,037	594,387		(30,149)		1,224,905		1,789,143
Net income	—	—		—		89,752		89,752
Foreign currency translation	—	—		412		—		412
Cash flow hedge, net of tax	—	—		(1,197)		—		(1,197)
Cash dividends	—	—		—		(18,239)		(18,239)
Dividends on RSUs	—	419		—		(419)		—
Purchases of Maximus common stock	(611)	—		—		(50,637)		(50,637)
Stock compensation expense	—	9,481		—		—		9,481

RSUs vested	1	—		—		—		—
Balance as of June 30, 2024	60,427	$	604,287	$	(30,934)	$	1,245,362	$	1,818,715

See accompanying notes to consolidated financial statements.

Table of Contents

Maximus, Inc.

Notes to the Consolidated Financial Statements

1. ORGANIZATION

Maximus, a Virginia corporation established in 1975 and celebrating its 50th anniversary this year, is a leading strategic partner to government agencies. Under our mission of Moving People Forward, Maximus helps improve the delivery of public services to millions of people amid complex technological, health, economic, environmental, and social challenges. As a trusted and experienced partner to local, state, federal, and international government clients, we proudly design, develop, and deliver innovative and impactful programs that change lives. We are driven to strengthen communities and improve the lives of those we serve.

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements, including the notes, include the accounts of the Company and its wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, and the rules and regulations of the SEC. All intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation for Interim Periods

Certain information and disclosures normally included for the annual financial statements to be prepared in accordance with U.S. GAAP have been condensed or omitted for the interim periods presented. We believe that the unaudited interim financial statements include all adjustments (which are normal and recurring in nature) necessary to present fairly our financial position and the results of operations and cash flows for the periods presented.

The results of operations for the interim periods presented are not necessarily indicative of results that may be expected for the year or future periods. The financial statements should be read in conjunction with our audited consolidated financial statements and the accompanying notes contained in our Annual Report on Form 10-K for the fiscal year ended September 30, 2024. We have continued to follow the accounting policies set forth in those financial statements.

Use of Estimates

The preparation of these financial statements, in conformity with U.S. GAAP, requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenue and expenses. At each reporting period end, we make estimates, including those related to revenue recognition and cost estimation on certain contracts, the realizability of long-lived assets, and amounts related to income taxes, certain accrued liabilities, and contingencies and litigation.

At June 30, 2025, our capitalized software balance includes $41.3 million related to technology for new services within our U.S. Services Segment. During the first quarter of fiscal year 2024, we evaluated these assets by comparing their carrying value to their estimated future cash flows. At that time, our probability-weighted undiscounted cash flows showed that we would recover the costs of these assets through our contract pipeline. We continue to monitor these assets. If circumstances change, we may be required to adjust the value or asset life of these assets.

Table of Contents

3. BUSINESS SEGMENTS

We conduct our operations through three business segments: U.S. Federal Services, U.S. Services, and Outside the U.S. Our operating segments represent the manner in which our Chief Executive Officer reviews our financial results.

U.S. Federal Services

Our U.S. Federal Services Segment delivers solutions that help various U.S. federal government agencies better deliver on their mission, including program operations and management, clinical services, and technology solutions. The segment also includes system and application development, Information Technology (IT) modernization, and maintenance services. Clinical services comprises appeals and assessments services, which includes managing the evaluation process for U.S. veterans and service members on behalf of the U.S. Department of Veterans Affairs (VA) and certain state-based assessments and appeals work that is part of the segment's heritage. Under Maximus Federal Technology Solutions (MFTS), the segment executes on its digital strategy to deliver technology solutions that advance agency missions, including the challenge to modernize, provide better customer experience, and drive process efficiencies.

U.S. Services

Our U.S. Services Segment provides a variety of services, such as program operations, clinical services, employment services and technology solutions, and related consulting work for U.S. state and local government programs. These services support a variety of programs, including the programs under the Affordable Care Act (ACA), Medicaid, the Children's Health Insurance Program (CHIP), Temporary Assistance to Needy Families (TANF), and child support programs. Program operations include comprehensive program administration services for government clients. The services we provide vary from program to program and include: centralized multilingual customer contact centers and multichannel, digital self-service options to better serve citizens' needs; application assistance to beneficiaries to help them access benefits; person centered clinical assessment services; provider enrollment systems and related business process services; employment services including eligibility support, case management, job-readiness preparation, job search and employer outreach, job retention and career advancement, and selected educational and training services. Our consulting services include technical and financial consulting services, including Independent Verification and Validation (IV&V) services, program modernization consulting; and project management.

Outside the U.S.

Our Outside the U.S. Segment provides business process services (BPS) and technology solutions for international governments. These services include health and disability assessments, program administration for employment services, wellbeing solutions and other job seeker-related services, digitally-enabled customer services, and advanced technologies for modernization. We support programs and deliver services in various locations, including the United Kingdom, where we serve the Functional Assessment Services (FAS) contract, which replaced the Health Assessment Advisory Service (HAAS) contract, and the Restart employment program. In recent years, we have divested components of this segment including, in the first quarter of fiscal year 2025, our businesses in Australia and Korea.

Table of Contents


Table 3.1: Results of Operations by Business Segment
	For the Three Months Ended								For the Nine Months Ended
	June 30, 2025				June 30, 2024				June 30, 2025				June 30, 2024
	Amount		% (1)		Amount		% (1)		Amount		% (1)		Amount		% (1)
	(dollars in thousands)
Revenue:
U.S. Federal Services	$	761,174			$	683,347			$	2,319,756			$	2,062,127
U.S. Services	439,818				472,298				1,334,418				1,448,258
Outside the U.S.	147,408				159,284				458,687				479,942
Revenue	$	1,348,400			$	1,314,929			$	4,112,861			$	3,990,327
Gross profit:
U.S. Federal Services	$	226,134	29.7	%	$	186,075	27.2	%	$	601,507	25.9	%	$	506,074	24.5	%
U.S. Services	105,932		24.1	%	121,012		25.6	%	312,706		23.4	%	369,497		25.5	%
Outside the U.S.	27,447		18.6	%	25,227		15.8	%	85,678		18.7	%	74,386		15.5	%
Gross profit	$	359,513	26.7	%	$	332,314	25.3	%	$	999,891	24.3	%	$	949,957	23.8	%
Selling, general, and administrative expenses:
U.S. Federal Services	$	88,272	11.6	%	$	79,949	11.7	%	$	245,563	10.6	%	$	247,671	12.0	%
U.S. Services	60,975		13.9	%	59,531		12.6	%	173,096		13.0	%	174,032		12.0	%
Outside the U.S.	21,507		14.6	%	26,647		16.7	%	66,822		14.6	%	75,249		15.7	%
Divestiture-related charges (2)	—		NM		—		NM		39,343		NM		1,018		NM
Other (3)	77		NM		906		NM		599		NM		6,712		NM
Selling, general, and administrative expenses	$	170,831	12.7	%	$	167,033	12.7	%	$	525,423	12.8	%	$	504,682	12.6	%
Operating income:
U.S. Federal Services	$	137,862	18.1	%	$	106,126	15.5	%	$	355,944	15.3	%	$	258,403	12.5	%
U.S. Services	44,957		10.2	%	61,481		13.0	%	139,610		10.5	%	195,465		13.5	%
Outside the U.S.	5,940		4.0	%	(1,420)		(0.9)	%	18,856		4.1	%	(863)		(0.2)	%
Amortization of intangible assets	(23,010)		NM		(23,542)		NM		(69,041)		NM		(68,532)		NM
Divestiture-related charges (2)	—		NM		—		NM		(39,343)		NM		(1,018)		NM
Other (3)	(77)		NM		(906)		NM		(599)		NM		(6,712)		NM
Operating income	$	165,672	12.3	%	$	141,739	10.8	%	$	405,427	9.9	%	$	376,743	9.4	%

(1)Percentage of respective revenue, as applicable. Percentages not considered meaningful are marked "NM."

(2)During fiscal years 2025 and 2024, we have divested businesses from our Outside the U.S. Segment. See "Note 6. Divestitures" for additional information.

(3)Other expenses include credits and costs that are not allocated to a particular segment.

Table of Contents

4. REVENUE RECOGNITION

We recognize revenue as, or when, we satisfy performance obligations under a contract. The majority of our contracts have performance obligations that are satisfied over time. In most cases, we view our performance obligations as promises to transfer a series of distinct services to our customers that are substantially the same and which have the same pattern of service. We recognize revenue over the performance period as a customer receives the benefits of our services.

Disaggregation of Revenue

In addition to our segment reporting, we disaggregate our revenues by service, contract type, and customer type.


Table 4.1: Revenue by Service Type
	For the Three Months Ended								For the Nine Months Ended
	June 30, 2025				June 30, 2024				June 30, 2025				June 30, 2024
	(dollars in thousands)
Program Operations	$	626,981	46.5	%	$	604,614	46.0	%	$	2,045,720	49.7	%	$	1,957,034	49.0	%
Clinical Services	560,360		41.6	%	506,077		38.5	%	1,535,849		37.3	%	1,401,069		35.1	%
Employment & Other	81,906		6.1	%	112,044		8.5	%	274,513		6.7	%	346,404		8.7	%
Technology Solutions	79,153		5.9	%	92,194		7.0	%	256,779		6.2	%	285,820		7.2	%
Total revenue	$	1,348,400			$	1,314,929			$	4,112,861			$	3,990,327


Table 4.2: Revenue by Contract Type
	For the Three Months Ended								For the Nine Months Ended
	June 30, 2025				June 30, 2024				June 30, 2025				June 30, 2024
	(in thousands)
Performance-based	$	761,428	56.5	%	$	758,942	57.7	%	$	2,193,605	53.3	%	$	2,202,541	55.2	%
Cost-plus	301,385		22.4	%	281,823		21.4	%	1,020,311		24.8	%	958,336		24.0	%
Fixed price	180,390		13.4	%	170,787		13.0	%	540,078		13.1	%	514,280		12.9	%
Time and materials	105,197		7.8	%	103,377		7.9	%	358,867		8.7	%	315,170		7.9	%
Total revenue	$	1,348,400			$	1,314,929			$	4,112,861			$	3,990,327


Table 4.3: Revenue by Customer Type
	For the Three Months Ended								For the Nine Months Ended
	June 30, 2025				June 30, 2024				June 30, 2025				June 30, 2024
	(dollars in thousands)
New York state government agencies	$	148,408	11.0	%	$	159,927	12.2	%	$	466,053	11.3	%	$	487,413	12.2	%
Other U.S. state government agencies	291,312		21.6	%	310,374		23.6	%	869,561		21.1	%	952,978		23.9	%
Total U.S. state government agencies	439,720				470,301				1,335,614				1,440,391
U.S. federal government agencies	743,058		55.1	%	666,895		50.7	%	2,267,078		55.1	%	2,015,780		50.5	%
International government agencies	146,018		10.8	%	156,587		11.9	%	451,608		11.0	%	468,995		11.8	%
Other, including local municipalities and commercial customers	19,604		1.5	%	21,146		1.6	%	58,561		1.4	%	65,161		1.6	%
Total revenue	$	1,348,400			$	1,314,929			$	4,112,861			$	3,990,327

Table of Contents

Contract balances

Differences in timing between revenue recognition and cash collection result in contract assets and contract liabilities. We classify these assets as accounts receivable — billed and billable and unbilled receivables; the liabilities are classified as deferred revenue.

In many contracts, we bill our customers on a monthly basis shortly after the month end for work performed in that month. Where such balances are billable and collectible under standard terms, they are included within accounts receivable, net.

Exceptions to this pattern will arise for various reasons, including those listed below.

•Under cost-plus contracts, we are typically required to estimate a contract's share of our general and administrative expenses. This share is based upon estimates of total costs, which may vary over time. We typically invoice our customers at an agreed provisional billing rate, which may differ from actual rates incurred. If our actual rates are higher than the provisional billing rates, an asset is recorded for this variance; if the provisional billing rates are higher than our actual rates, we record a liability.

•Certain contracts include retainage balances, whereby revenue is earned, but some portion of cash payments are held back by the customer for a period of time, typically to allow the customer to confirm the objective criteria laid out by the contract have been met. This balance is classified as accounts receivable - unbilled until restrictions on billing are lifted. As of June 30, 2025, and September 30, 2024, $26.5 million and $31.9 million, respectively, of our unbilled receivables are related to amounts pursuant to contractual retainage provisions.

•In certain contracts, we may receive funds from our customers prior to performing operations. These funds are typically referred to as "set-up costs" and reflect the need for us to make investments in infrastructure prior to providing a service. This investment in infrastructure is not a performance obligation that is distinct from the service that is subsequently provided and, as a result, revenue is not recognized based upon the establishment of this infrastructure, but rather over the course of the contractual relationship. The funds are initially recorded as deferred revenue and recognized over the term of the contract. Other contracts may not include set-up fees but will provide higher fees in earlier periods of the contract. The premium on these fees is deferred.

•Some of our contracts, notably our employment services contracts in the Outside the U.S. Segment, include payments for desired outcomes, such as job placement and job retention, and these outcome payments occur over several months. We are required to estimate these outcome fees ahead of their realization and recognize this estimated fee over the period of delivery.

During the three and nine months ended June 30, 2025, we recognized revenue of $13.8 million and $87.0 million, respectively, included in our deferred revenue balances at September 30, 2024. During the three and nine months ended June 30, 2024, we recognized revenue of $8.2 million and $53.5 million, respectively, included in our deferred revenue balances at September 30, 2023.

Contract estimates

We are required to use estimates in recognizing revenue from some of our contracts.

Certain performance-based contracts include variable consideration in the form of penalties and incentives, based upon our performance under the terms of the contract. The calculation of these penalties and incentives requires the evaluation of both objective and subjective criteria, which may require the use of estimates.

Within our employment services business in our Outside the U.S. Segment, some of our performance-based contract revenue is recognized based upon future milestones defined in each contract, which requires us to make estimates about the attainment of the milestones.

We estimate the total variable consideration we will receive using the expected value method. We recognize the revenue over the expected period of performance. At each reporting period, we update our estimates of the variable fees to represent the circumstances present at the end of the reporting period. We are required to constrain our estimates to the extent that it is probable that there will not be a significant reversal of cumulative revenue when the uncertainty is resolved. We do not have a history of significant constraints on these contracts.

Table of Contents


Table 4.4: Effect of Changes in Contract Estimates
	For the Three Months Ended				For the Nine Months Ended
	June 30, 2025		June 30, 2024		June 30, 2025		June 30, 2024
	(in thousands, except per share data)
Increase in/(reduction of) revenue recognized due to changes in contract estimates	$	607	$	(3,576)	$	11,181	$	(12,772)
Increase in/(reduction of) diluted earnings per share recognized due to changes in contract estimates	$	0.01	$	(0.04)	$	0.14	$	(0.16)

Remaining performance obligations

As of June 30, 2025, we had approximately $330 million of remaining performance obligations, with obligations running through March 2032. We anticipate that most of the obligations will be settled within a shorter period of time, with 63% of this balance being utilized within the next 12 months. This balance excludes contracts with an original duration of twelve months or less, including contracts with a penalty-free termination for convenience clause, and any variable consideration that is allocated entirely to future performance obligations, including variable transaction fees or fees tied directly to costs incurred.

5. EARNINGS PER SHARE


Table 5: Weighted Average Number of Shares - Earnings Per Share
	For the Three Months Ended		For the Nine Months Ended
	June 30, 2025	June 30, 2024	June 30, 2025	June 30, 2024
	(in thousands)
Basic weighted average shares outstanding	56,683	61,079	57,776	61,233
Dilutive effect of unvested RSUs and PSUs	301	302	324	262
Denominator for diluted earnings per share	56,984	61,381	58,100	61,495

The diluted earnings per share calculation for the three and nine months ended June 30, 2025 excludes approximately 140,000 and 142,000 unvested anti-dilutive restricted stock units, respectively. The diluted earnings per share calculation for the three and nine months ended June 30, 2024 excludes approximately 212,000 and 216,000 unvested anti-dilutive restricted stock units, respectively.

6. DIVESTITURES

We have recently made divestitures from our Outside the U.S. Segment.

In December 2024, we sold our businesses in Australia and Korea for a nominal sum. The sale agreement includes up to $5.0 million of contingent consideration based upon future performance. As of June 30, 2025, we have not recorded any potential contingent consideration. Our divestiture-related charges of $39.3 million included approximately $21.3 million of previously unrealized foreign exchange losses, which we had recorded through other comprehensive income. The divestiture-related charges are recorded as "selling, general, and administrative expenses" on our consolidated statements of operations. We also provided an indemnification to the buyer, the fair value of which we estimate to be $11.0 million. No tax benefit is anticipated from this transaction.

In November 2023, we sold our businesses in Italy and Singapore, as well as our employment services business in Canada, recording a loss of $1.0 million.

Table of Contents

7. DEBT AND DERIVATIVES


Table 7.1: Details of Debt
	June 30, 2025		September 30, 2024
	(in thousands)
Term Loan A (TLA)	$	864,375	$	641,875
Term Loan B (TLB)	495,000		498,750
Revolver	310,000		—
Subsidiary loan agreements	1,208		5,194
Total debt principal	1,670,583		1,145,819
Less: Unamortized debt-issuance costs and discounts	(13,338)		(13,726)
Total debt	1,657,245		1,132,093
Less: Current portion of long-term debt	(48,263)		(40,139)
Long-term debt	$	1,608,982	$	1,091,954

On March 20, 2025, we amended our existing credit agreement (the "Amendment") with J.P. Morgan Chase Bank, N.A. The Amendment increased our Term Loan A facility (TLA) by $250 million, leaving all other terms and conditions unchanged. Such amounts are available for general corporate purposes, including the funding of working capital, capital expenditures, and possible future acquisitions. Costs related to the Amendment have been reported as a reduction to the debt principal and will be amortized over the remaining term of the agreement.

Our credit agreements require us to comply with a number of covenants, including leverage and interest coverage ratios. At June 30, 2025, we are in compliance with all covenants. We do not believe that the covenants represent a significant restriction on our ability to successfully operate the business or to pay dividends.

The following table sets forth future minimum principal payments due under our debt obligations as of June 30, 2025 for the remainder of fiscal year 2025 through fiscal year 2031:


Table 7.2: Details of Future Minimum Principal Payments Due
	Amount Due
	(in thousands)
July 1, 2025 through September 30, 2025	$	13,708
Year ended September 30, 2026	55,625
Year ended September 30, 2027	72,500
Year ended September 30, 2028	78,125
Year ended September 30, 2029	976,875
Years ended thereafter	473,750
Total payments	$	1,670,583

Interest Rate Derivative Instruments

We utilize interest rate swaps that are designed to reduce our risk from changes in interest rates, which we have designated as cash flow hedges. The following table presents our interest rate swaps:


Table 7.3: Interest Rate Derivative Instruments
	As of June 30, 2025
	Notional Amount		Fixed Interest Rate
	(in thousands)
Term Loan B - Hedged through September 2025	$	75,000	4.09	%
Term Loan A - Hedged through May 2026	$	500,000	2.31	%
Term Loan B - Hedged through September 2026	$	75,000	3.72	%
Term Loan A - Hedged from June 2026 through September 2027	$	150,000	3.14	%
Term Loan A - Hedged from June 2026 through September 2028	$	100,000	3.19	%

Table of Contents

The balance of the debt pays interest based upon the SOFR. At June 30, 2025, our effective interest rate, including the original issuance costs and discount rate, was 5.5%.

At June 30, 2025, we recorded an asset of $8.0 million and a liability of $1.1 million to reflect the fair value of our interest rate swap agreements, compared to an asset of $12.6 million and a liability of $3.4 million at September 30, 2024. The asset and liability are recorded as "other assets" and "other liabilities," respectively, within our consolidated balance sheets. As these instruments are effective cash flow hedges, gains and losses based upon interest rate fluctuations are recorded within "accumulated other comprehensive income" within our consolidated financial statements.

In July 2025, we entered into two interest rate swap agreements for a combined notional amount of $125.0 million. The first arrangement is for a notional amount of $50.0 million and hedges a SOFR component of our TLA to a fixed amount of 3.46%. This arrangement will become effective in June 2026 and expire in September 2028. The second arrangement is for a notional amount of $75.0 million and hedges a SOFR component of our TLB to a fixed amount of 3.62%. This arrangement will become effective in October 2025 and expire in September 2027.

8. FAIR VALUE MEASUREMENTS

The following assets and liabilities are recorded at fair value on a recurring basis.

•We hold mutual fund assets within a Rabbi Trust to cover liabilities in our deferred compensation plan. These assets have prices quoted within active markets and, accordingly, are classified as level 1 within the fair value hierarchy.

•We have interest rate swap agreements serving to reduce our interest rate risk on our debt. These agreements can be valued using observable data and, accordingly, are classified as level 2 within the fair value hierarchy.

•In connection with the businesses sold in Australia and Korea, we indemnified the buyer related to certain potential losses, which are recorded at fair value, based on an assessment of probability-weighted outcomes. Accordingly, these inputs are not observable and are classified as level 3 within the fair value hierarchy. Changes in the fair value of the indemnification liability are recorded in the consolidated statements of operations.

The table below presents assets and liabilities measured and recorded at fair value in our consolidated balance sheets on a recurring basis and their corresponding level within the fair value hierarchy. No transfers between Level 1, Level 2, and Level 3 fair value measurements occurred for the nine months ended June 30, 2025.


Table 8.1: Fair Value Measurements
	As of June 30, 2025
	Level 1		Level 2		Level 3		Balance
	(in thousands)
Assets:
Deferred compensation assets - Rabbi Trust	$	38,141	$	—	$	—	$	38,141
Interest rate swap - $375 million notional value	—		7,984		—		7,984
Total assets	$	38,141	$	7,984	$	—	$	46,125
Liabilities:
Interest rate swap - $525 million notional value	$	—	$	1,074	$	—	$	1,074
Indemnification liabilities	—		—		11,048		11,048
Total liabilities	$	—	$	1,074	$	11,048	$	12,122

The fair values of receivables, prepaid assets, other assets, accounts payable, accrued costs, and other current liabilities approximate the carrying values as a result of the short-term nature of these instruments. The carrying value of our debt is consistent with the fair value as the stated interest rates in the agreements are consistent with the current market rates used in notes with similar terms in the markets (Level 2 inputs).

Table of Contents

Accumulated Other Comprehensive Loss

All amounts recorded in accumulated other comprehensive loss are related to our foreign currency translations and interest rate swaps, net of tax. The following table shows changes in accumulated other comprehensive loss. Amounts reclassified from other comprehensive income were recorded within our selling, general, and administrative expenses (for foreign currency translation adjustments) and within interest expense (for gains on derivatives).


Table 8.2: Details of Changes in Accumulated Other Comprehensive Loss by Category
	Foreign currency translation adjustment		Net unrealized gain on derivatives, net of tax		Total
	(in thousands)
Balance as of September 30, 2024	$	(39,225)	$	6,765	$	(32,460)
Other comprehensive income before reclassifications	231		4,784		5,015
Amounts reclassified from accumulated other comprehensive loss	21,272		(6,456)		14,816
Net current period other comprehensive income/(loss)	21,503		(1,672)		19,831
Balance as of June 30, 2025	$	(17,722)	$	5,093	$	(12,629)

9. EQUITY

Stock Compensation

We grant restricted stock units (RSUs) and performance stock units (PSUs) to eligible participants under our 2021 Omnibus Incentive Plan, which was approved by the Board of Directors and stockholders. The RSUs granted to employees vest ratably over three to four years, and one year for members of the Board of Directors, in each case from the grant date. PSU vesting is subject to the achievement of certain performance and market conditions, and the number of PSUs earned could vary from 0% to 200% of the number of PSUs awarded. The PSUs will vest at the end of a three-year performance period if the performance conditions are met. We issue new shares to satisfy our obligations under these plans. The fair value of each RSU and PSU is calculated at the date of the grant.

During the nine months ended June 30, 2025, we issued approximately 364,000 RSUs, which will vest ratably over one to four years, and approximately 154,000 PSUs, which will vest after three years if the performance conditions are met.

Stock Repurchase Programs

Under resolutions adopted in June 2024 and December 2024, the Board of Directors authorized an increase to our existing stock purchase program that allows us to purchase, at management's discretion, up to $400 million of our common stock.

During the nine months ended June 30, 2025, we purchased approximately 4.1 million common shares at a cost of $309.5 million, which includes an additional charge from the 1% excise tax on share purchases. During the three and nine months ended June 30, 2024, we purchased approximately 0.6 million common shares at a cost of $50.6 million.

At June 30, 2025, $65.8 million remained available for future stock purchases.

Table of Contents

10. OTHER ITEMS

Cash, Cash Equivalents, and Restricted Cash


Table 10.1: Details of Cash and Cash Equivalents and Restricted Cash
	June 30, 2025		September 30, 2024
	(in thousands)
Cash and cash equivalents	$	59,777	$	183,123
Restricted cash	45,599		52,640
Cash, cash equivalents, and restricted cash	$	105,376	$	235,763

Restricted cash is recorded within "Prepaid expenses and other current assets" on the Consolidated Balance Sheets.


Table 10.2: Supplemental Disclosures of Cash Flow Information
	For the Nine Months Ended
	June 30, 2025		June 30, 2024
	(in thousands)
Interest payments	$	60,809	$	59,367
Income tax payments	$	100,891	$	67,822

Accounts Receivable, Net


Table 10.3: Details of Accounts Receivable, Net
	June 30, 2025		September 30, 2024
	(in thousands)
Billed and billable receivables	$	1,030,340	$	734,817
Unbilled receivables	401,547		149,488
Allowance for credit losses	(9,537)		(4,791)
Accounts receivable, net	$	1,422,350	$	879,514

We have a Receivables Purchase Agreement (RPA) with Wells Fargo Bank N.A., under which we may sell certain U.S.-originated accounts receivable balances up to a maximum amount of $200.0 million at any given time. In return for these sales, we receive a cash payment equal to the face value of the receivables less a financing charge.

We account for these transfers as sales. We have no retained interest in the transferred receivables other than administrative responsibilities, and Wells Fargo has no recourse for any credit risk. We estimate that the implicit servicing fees for an arrangement of this size and type would be immaterial.

For the nine months ended June 30, 2025 and 2024, the gross fair value of accounts receivables transferred to Wells Fargo and derecognized from our balance sheet was $574.2 million and $270.9 million, respectively. In exchange for these sales, we received cash of $570.7 million and $269.3 million for the same periods, respectively. The difference, representing a loss on sale from these transfers, is included within our selling, general, and administrative expenses. We have recorded these transactions within our operating cash flows.

Table of Contents

11. COMMITMENTS AND CONTINGENCIES

Litigation

We are subject to audits, investigations, and reviews relating to compliance with the laws and regulations that govern our role as a contractor to agencies and departments of federal, state, local, and foreign governments. Adverse findings could lead to criminal, civil, or administrative proceedings, and we could be faced with penalties, fines, suspension, or debarment. Adverse findings could also have a material adverse effect on us because of our reliance on government contracts. We are subject to periodic audits by federal, state, local, and foreign governments for taxes. We are also involved in various claims, arbitrations, and lawsuits arising in the normal conduct of our business, which include but are not limited to bid protests, employment matters, contractual disputes, and charges before administrative agencies. Except for the matters described below for which we cannot predict the outcome, we do not believe the outcome of any existing matter would likely have a material adverse effect on our consolidated financial position, results of operations, or cash flows.

We evaluate developments in our litigation matters and establish or make adjustments to our accruals as appropriate. A liability is accrued if a loss is probable and the amount of such loss can be reasonably estimated. If the risk of loss is probable, but the amount cannot be reasonably estimated, or the risk of loss is only reasonably possible, a potential liability will be disclosed but not accrued, if material. Due to the inherent uncertainty in the outcome of litigation, our estimates and assessments may prove to be incomplete or inaccurate and could be impacted by unanticipated events and circumstances, adverse outcomes, or other future determinations.

MOVEit Cybersecurity Incident Litigation

As the Company has previously disclosed, on May 31, 2023, Progress Software Corporation, the developer of MOVEit, a file transfer application used by many organizations to transfer data, announced a critical zero-day vulnerability in the application that allowed unauthorized third parties to access its customers’ MOVEit environments. Maximus uses MOVEit for internal and external file sharing purposes, including to share data with government customers related to Maximus's services in support of certain government programs. Based on its review of the impacted files to date, the Company has provided notices to individuals whose personal information, including social security numbers, protected health information, and/or other personal information, may have been included in the impacted files.

On August 1, 2023, a purported class action was filed against Maximus Federal Services, Inc. (a wholly-owned subsidiary of Maximus, Inc.) in the U.S. District Court for the Eastern District of Virginia arising out of the MOVEit cybersecurity incident – Bishop v. Maximus Federal Services, Case No. 1:23-cv-01019 (U.S. Dist. Ct. E. D. VA). The plaintiff, who purports to represent a nationwide class of individuals, alleges, among other things, that the Company’s negligence resulted in the compromise of the plaintiff’s personally identifiable information and protected health information. The plaintiff seeks damages to be proved at trial. Since then, thirteen similar cases have been filed in federal courts across the country (inclusive of one case filed in state court and removed to federal court by the Company).

On October 4, 2023, the United States Judicial Panel on Multidistrict Litigation granted a Motion to Transfer creating a Multidistrict Litigation (MDL) in the District of Massachusetts for all cases related to the MOVEit cybersecurity incident. Each of the actions pending in federal courts are centralized in the MDL.

On December 12, 2024, the Court granted in part Defendants' omnibus motion to dismiss Plaintiffs’ claims pursuant to Rule 12(b)(1), challenging Plaintiffs’ standing to bring this suit, dismissing claims brought by four of the Plaintiffs in the MOVEit MDL. None of the dismissed claims were asserted against the Company.

The Court has also named the Company as a bellwether defendant in the MDL. The Company and the other bellwether defendants submitted motions to dismiss the pending actions pursuant to Rule 12(b)(6), which the Court granted in part and denied in part on July 31, 2025. Approximately half of the claims asserted against the Company remain, and the Company is proceeding to discovery regarding those claims.

Separately, there is currently an individual action pending against the Company in Florida state court. On September 6, 2023, an individual action related to the MOVEit incident was filed in state court in the Florida Circuit Court for the 7th Judicial Circuit, Volusia County: Taylor v. Maximus Federal Services, Case No. 2023-12349 (Fla. Cir. Ct., 7th Jud. Cir., Volusia Cnty.). The plaintiff alleges, among other things, that the Company’s negligence resulted in the compromise of the plaintiff’s personally identifiable information and protected health information. The plaintiff seeks damages to be proved at trial. On April 3, 2024, the Court stayed this action pending further developments in the MOVEit MDL. This case remains stayed.

Table of Contents

While the Company is unable to predict the ultimate outcome of any of the remaining proceedings, we have accrued an amount within a range of possible outcomes expected to be incurred to resolve the matters.

12. SUBSEQUENT EVENT

On July 5, 2025, our Board of Directors declared a quarterly cash dividend of $0.30 for each share of our common stock outstanding. The dividend is payable on August 31, 2025, to shareholders of record on August 15, 2025. Based upon the number of shares outstanding, we anticipate a cash payment of approximately $16.9 million.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion is intended to help the reader understand our business, financial condition, results of operations, liquidity and capital resources. You should read this discussion in conjunction with "Risk Factors," "Special Note Regarding Forward-Looking Statements," and our financial statements and related notes included in our Annual Report on Form 10-K for fiscal year 2024 filed with the SEC on November 21, 2024 and elsewhere in this Quarterly Report on Form 10-Q, as applicable.

Business Overview

Maximus, under its mission of Moving People Forward and celebrating its 50th anniversary this year, helps millions of people access the vital government services they need. As a trusted and experienced partner to local, state, federal, and international government clients, we proudly design, develop, and deliver innovative and impactful programs that change lives. We are driven to strengthen communities and improve the lives of those we serve.

We create value for our customers through our ability to translate health and human services public policy into operating models that achieve outcomes for governments at scale. Our work covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. These services benefit from a market with increasing demographic demand, constrained government budgets, and an increased focus on technology as governments prioritize modernization. We also demonstrate the ability to move quickly, ranging from digitally enabled contact center support services for natural disaster response to swift establishments of public health and safety initiatives, examples of which occurred during the COVID-19 pandemic. Our organic growth has occurred through increased contract scope and entry into new markets. In addition, we have made strategic acquisitions, intended to drive additional organic growth through new capabilities or customer sets gained.

We continue to execute on our strategic plan introduced in fiscal year 2022. We believe in further expansion of our business and remain in a strong position to capitalize on organic growth opportunities in our core business. Our strategic plan consists of three central pillars:

•Customer Services, Digitally Enabled. Elevate the customer experience to achieve higher levels of satisfaction, performance, and outcomes through intelligent automation and cognitive computing. The launch of Maximus Total Experience Management (TXM) is evidence of this focus and commitment. TXM is an integrated solution designed to help federal agencies deliver trusted information and government services simply, consistently, and securely. This new differentiated solution seamlessly integrates people, experience, data insights, and secure technologies into one digitally powered platform to reimagine government service delivery.

•Future of Health. Help governments reach the rising demand for health services by growing our clinical capabilities and increasing the level of sophistication of underlying tools to improve the health of people and their communities.

•Advanced Technologies for Modernization. Further our credibility as a technology leader, enabling the transformation of government programs and legacy system environments to be resilient, dynamic, integrated, and equitable.

Our strategic plan is aligned with specific opportunities within all three of our segments and includes a common focus on optimizing processes and simplifying our structure under our Maximus Forward corporate initiative. We also continue to focus on our people - the foundation of our strategy. As an employer of choice, our goal is to continue to prioritize attracting, retaining, developing, and empowering employees as a central part of our plan for achieving future growth.

Table of Contents

Financial Overview

Commencing in the second quarter of the current fiscal year, Maximus has experienced some short-term delays in cash flow as a result of administrative delays in billing and contract approval with customers in our U.S. Federal and U.S. Services Segments. Such delays are not unusual within our business, although the scale and timing of these delays has been greater than what we typically experience. These delays have resulted in a significant increase in our receivables balances. As a result, we have used additional borrowings under our revolving credit facility, with corresponding increases in interest expense. During July 2025, we have seen significant progress in resolving these delays, and we continue to anticipate returning to a normal level of receivables towards the end of the fourth quarter of this fiscal year.

Results of Operations

The following table sets forth items from our consolidated statements of operations for the three and nine months ended June 30, 2025, and June 30, 2024.


Table MD&A 1: Consolidated Results of Operations
	For the Three Months Ended						For the Nine Months Ended
	June 30, 2025			June 30, 2024			June 30, 2025			June 30, 2024
	(dollars in thousands, except per share data)
Revenue	$	1,348,400		$	1,314,929		$	4,112,861		$	3,990,327
Cost of revenue	988,887			982,615			3,112,970			3,040,370
Gross profit	359,513			332,314			999,891			949,957
Gross profit percentage	26.7		%	25.3		%	24.3		%	23.8		%
Selling, general, and administrative expenses	170,831			167,033			525,423			504,682
Selling, general, and administrative expenses as a percentage of revenue	12.7		%	12.7		%	12.8		%	12.6		%
Amortization of intangible assets	23,010			23,542			69,041			68,532
Operating income	165,672			141,739			405,427			376,743
Operating margin	12.3		%	10.8		%	9.9		%	9.4		%
Interest expense	22,657			20,555			61,648			62,428
Other expense/(income), net	48			809			(603)			475
Income before income taxes	142,967			120,375			344,382			313,840
Provision for income taxes	36,986			30,623			100,636			79,430
Effective tax rate	25.9		%	25.4		%	29.2		%	25.3		%
Net income	$	105,981		$	89,752		$	243,746		$	234,410
Earnings per share:
Basic	$	1.87		$	1.47		$	4.22		$	3.83
Diluted	$	1.86		$	1.46		$	4.20		$	3.81

Our business segments have different factors driving revenue fluctuations and profitability. The sections that follow cover these segments in greater detail. Our revenue reflects fees earned for services provided. Cost of revenue consists of direct costs related to labor and related overhead, subcontractor labor, outside vendors, rent, and other direct costs. The largest component of cost of revenue, approximately two-thirds, is labor, including subcontracted labor.


Table MD&A 2: Changes in Revenue, Cost of Revenue, and Gross Profit for the Three Months Ended June 30, 2025
	Revenue				Cost of Revenue				Gross Profit
	Dollars		% Change		Dollars		% Change		Dollars		% Change
	(dollars in thousands)
Three Months Ended June 30, 2024	$	1,314,929			$	982,615			$	332,314
Organic effect	57,015		4.3	%	25,775		2.6	%	31,240		9.4	%
Disposal of businesses	(29,557)		(2.2)	%	(24,813)		(2.5)	%	(4,744)		(1.4)	%

Currency effect compared to the prior period	6,013		0.5	%	5,310		0.5	%	703		0.2	%
Three Months Ended June 30, 2025	$	1,348,400	2.5	%	$	988,887	0.6	%	$	359,513	8.2	%

Table of Contents


Table MD&A 3: Changes in Revenue, Cost of Revenue, and Gross Profit for the Nine Months Ended June 30, 2025
	Revenue				Cost of Revenue				Gross Profit
	Dollars		% Change		Dollars		% Change		Dollars		% Change
	(dollars in thousands)
Nine Months Ended June 30, 2024	$	3,990,327			$	3,040,370			$	949,957
Organic effect	179,904		4.5	%	125,671		4.1	%	54,233		5.7	%
Disposal of businesses	(65,126)		(1.6)	%	(59,820)		(2.0)	%	(5,306)		(0.6)	%

Currency effect compared to the prior period	7,756		0.2	%	6,749		0.2	%	1,007		0.1	%
Nine Months Ended June 30, 2025	$	4,112,861	3.1	%	$	3,112,970	2.4	%	$	999,891	5.3	%

Selling, general, and administrative expenses

Selling, general, and administrative expenses consist of indirect costs related to general management, marketing, and administration. It is primarily composed of labor costs. These costs may be incurred at a segment level, for dedicated resources that are not client-facing, or at a corporate level. Corporate costs are allocated to segments on a consistent and rational basis. Fluctuations in our SG&A are primarily driven by changes in our administrative cost base, which are not directly driven by changes in our revenue. As part of our work for the U.S. federal government and many states, we allocate these costs using a methodology driven by the U.S. Federal Cost Accounting Standards.

Our SG&A expense for the nine months ended June 30, 2025, includes $39.3 million of divestiture-related charges from our sale of businesses in the Outside the U.S. Segment. These charges included accumulated foreign currency losses incurred over two decades of operations, as well as indemnifications provided to the buyer.

Amortization of intangible assets

Amortization of intangible assets remained consistent for the three and nine months ended June 30, 2025, as compared to the same periods in fiscal year 2024.

Our balance sheet includes $422.9 million of intangible assets from a 2021 acquisition. These assets, comprised of customer relationships, technology, and a medical provider network, continue to support medical disability examinations (MDE) contracts with the VA. Substantially all of these assets are being amortized over the remaining eight years. In the event that our expectations change with respect to these acquired contracts, the value of these assets and the estimated remaining lives of these assets may need to be adjusted.

Interest Expense

As disclosed above, delays in payments from customers have resulted in additional borrowings under our revolving credit facility, resulting in higher interest expense for the three months ended June 30, 2025, compared to the same period in fiscal year 2024. The full year effect of this increase for fiscal year 2025 has been mitigated by lower interest rates. We continue to mitigate a portion of our interest rate risk through hedging transactions on approximately half of our outstanding debt.

Provision for Income Taxes

Our effective income tax rate for the three and nine months ended June 30, 2025, was 25.9% and 29.2%, respectively, compared to 25.4% and 25.3% for the three and nine months ended June 30, 2024, respectively. The year-to-date rate increase is a result of the disposition of our businesses in Australia and Korea, which negatively impacted the effective tax rate. For fiscal year 2025, we expect an overall effective tax rate between 28.0% and 29.0%, inclusive of the divestiture and other non-recurring items, which negatively impact our full-year rate.

On July 4, 2025 the One Big Beautiful Bill Act (OBBB) was signed. We do not believe it will have a significant impact on the fiscal year 2025 effective tax rate or provision for income taxes. However, we anticipate a favorable cash tax impact in fiscal year 2026.

Table of Contents

U.S. Federal Services Segment


Table MD&A 4: U.S. Federal Services Segment - Financial Results
	For the Three Months Ended				For the Nine Months Ended
	June 30, 2025		June 30, 2024		June 30, 2025		June 30, 2024
	(dollars in thousands)
Revenue	$	761,174	$	683,347	$	2,319,756	$	2,062,127
Cost of revenue	535,040		497,272		1,718,249		1,556,053
Gross profit	226,134		186,075		601,507		506,074
Selling, general, and administrative expenses	88,272		79,949		245,563		247,671
Operating income	137,862		106,126		355,944		258,403
Gross profit percentage	29.7 %		27.2 %		25.9 %		24.5 %
Operating margin percentage	18.1 %		15.5 %		15.3 %		12.5 %

Our revenue and cost of revenue for the three months ended June 30, 2025 and 2024, increased 11.4% and 7.6%, respectively. For the nine months ended June 30, 2025 and 2024, our revenue and cost of revenue increased 12.5% and 10.4%, respectively.

Our revenue growth continues to be driven by clinical programs, including medical assessments, as well as broad growth across our portfolio of contracts. Our medical assessment revenue through the first three quarters of fiscal year 2025 benefited from increased volumes and performance improvements, which reduced the volume of penalties incurred. These volume increases include those driven by the Honoring our PACT Act, which had necessitated a contract rebid to expand the scale of these arrangements, as well as additional volume to keep up with assessment demand. These additional volumes also enhanced our profit margins. Fiscal year 2025 also benefited from support provided to the Federal Emergency Management Agency (FEMA). We have long-standing arrangements with FEMA to provide short-term assistance for natural disasters, the extent and timing of which are difficult to predict.

We anticipate a full-year operating margin of approximately 15% in fiscal year 2025.

Table of Contents

U.S. Services Segment


Table MD&A 5: U.S. Services Segment - Financial Results
	For the Three Months Ended				For the Nine Months Ended
	June 30, 2025		June 30, 2024		June 30, 2025		June 30, 2024
	(dollars in thousands)
Revenue	$	439,818	$	472,298	$	1,334,418	$	1,448,258
Cost of revenue	333,886		351,286		1,021,712		1,078,761
Gross profit	105,932		121,012		312,706		369,497
Selling, general, and administrative expenses	60,975		59,531		173,096		174,032
Operating income	44,957		61,481		139,610		195,465
Gross profit percentage	24.1 %		25.6 %		23.4 %		25.5 %
Operating margin percentage	10.2 %		13.0 %		10.5 %		13.5 %

Our revenue and cost of revenue for the three months ended June 30, 2025 and 2024, decreased 6.9% and 5.0%, respectively. For the nine months ended June 30, 2025 and 2024, our revenue and cost of revenue decreased 7.9% and 5.3%, respectively.

As disclosed at the time, our business in the first three quarters of fiscal year 2024 was experiencing higher volumes from the resumption of Medicaid redetermination activities, driving benefits in both revenue and margins. Our business had returned to normal activity levels by the fourth quarter of fiscal year 2024.

We anticipate a full-year operating margin of approximately 10.5% for this segment in fiscal year 2025.

Table of Contents

Outside the U.S. Segment

Our Outside the U.S. Segment provides business process services (BPS) and technology solutions for international governments. These services include health and disability assessments, program administration for employment services, wellbeing solutions and other job seeker-related services, digitally-enabled customer services, and advanced technologies for modernization. We support programs and deliver services in various locations, including the United Kingdom, where we serve the Functional Assessment Services (FAS) contract, which replaced the Health Assessment Advisory Service (HAAS) contract, and the Restart employment program. In recent years, we have divested components of the segment including, in the first quarter of fiscal year 2025, our businesses in Australia and Korea.


Table MD&A 6: Outside the U.S. Segment - Financial Results
	For the Three Months Ended				For the Nine Months Ended
	June 30, 2025		June 30, 2024		June 30, 2025		June 30, 2024
	(dollars in thousands)
Revenue	$	147,408	$	159,284	$	458,687	$	479,942
Cost of revenue	119,961		134,057		373,009		405,556
Gross profit	27,447		25,227		85,678		74,386
Selling, general, and administrative expenses	21,507		26,647		66,822		75,249
Operating income/(loss)	5,940		(1,420)		18,856		(863)
Gross profit percentage	18.6 %		15.8 %		18.7 %		15.5 %
Operating margin percentage	4.0 %		(0.9) %		4.1 %		(0.2) %


Table MD&A 7: Outside the U.S. Segment - Changes in Revenue, Cost of Revenue, and Gross Profit for the Three Months Ended June 30, 2025
	Revenue				Cost of Revenue				Gross Profit
	Amount		% Change		Amount		% Change		Amount		% Change
	(dollars in thousands)
Three Months Ended June 30, 2024	$	159,284			$	134,057			$	25,227
Organic effect	11,668		7.3	%	5,407		4.0	%	6,261		24.8	%
Disposal of businesses	(29,557)		(18.6)	%	(24,813)		(18.5)	%	(4,744)		(18.8)	%

Currency effect compared to the prior period	6,013		3.8	%	5,310		4.0	%	703		2.8	%
Three Months Ended June 30, 2025	$	147,408	(7.5)	%	$	119,961	(10.5)	%	$	27,447	8.8	%


Table MD&A 8: Outside the U.S. Segment - Changes in Revenue, Cost of Revenue, and Gross Profit for the Nine Months Ended June 30, 2025
	Revenue				Cost of Revenue				Gross Profit
	Amount		% Change		Amount		% Change		Amount		% Change
	(dollars in thousands)
Nine Months Ended June 30, 2024	$	479,942			$	405,556			$	74,386
Organic effect	36,115		7.5	%	20,524		5.1	%	15,591		21.0	%
Disposal of businesses	(65,126)		(13.6)	%	(59,820)		(14.8)	%	(5,306)		(7.1)	%

Currency effect compared to the prior period	7,756		1.6	%	6,749		1.7	%	1,007		1.4	%
Nine Months Ended June 30, 2025	$	458,687	(4.4)	%	$	373,009	(8.0)	%	$	85,678	15.2	%

This segment has moved from roughly breakeven to profitability between fiscal years 2024 and 2025.

We divested a number of employment services businesses over the past two years. The most significant divestiture impacting the results above is the sale of our operations in Australia and Korea in the first quarter of fiscal year 2025, which has reduced revenue and costs but provided a benefit to margin.

Organic growth was achieved across the portfolio, including the FAS contract in the United Kingdom and other volume-based arrangements.

We anticipate the full-year operating margin will range between 3% and 5% for this segment in fiscal year 2025.

Table of Contents

Liquidity and Capital Resources

Our primary sources of liquidity are cash on hand, cash from operations, and availability under our revolving credit facilities. As of June 30, 2025, we had $59.8 million in cash and cash equivalents. We believe that our current cash position, access to our revolving debt, and cash flow generated from operations should be sufficient for our operating requirements for the next 12 months and beyond, including enabling us to fund required long-term debt repayments, dividends, and any share purchases we might choose to make. See "Note 7. Debt and Derivatives" to the Consolidated Financial Statements for a more detailed discussion of our debt financing arrangements.

We have included the following table showing our debt balances as of June 30, 2025, and their effective interest rates.


Table MD&A 9: Debt Balances and Interest Rates as of June 30, 2025
	June 30, 2025
	Carrying value		Effective cash interest rate		Interest rate basis
	(dollars in thousands)
Term Loan A - Hedged through May 2026	$	500,000	3.68	%	Fixed rate of 2.31% plus margin. (1)
Term Loan A - Unhedged	364,375		5.70	%	Term SOFR reset monthly plus margin. (1)
Term Loan B - Hedged through September 2026	75,000		5.72	%	Fixed Rate of 3.72% plus 2% margin.
Term Loan B - Hedged through September 2025	75,000		6.09	%	Fixed Rate of 4.09% plus 2% margin.
Term Loan B - Unhedged	345,000		6.33	%	Term SOFR reset monthly plus 2% margin.
Revolver	310,000		5.70	%	Term SOFR reset monthly plus margin. (1)
Debt held by international subsidiaries	1,208		5.95	%	Floating rate, reset quarterly.
Debt Principal	$	1,670,583

(1) The margin ranges between 1% and 2%, based upon our leverage ratio. At June 30, 2025, the margin was 1.375%.

Our effective interest rate reflects the drivers of our cash interest payments as of June 30, 2025, which can change based upon the reset of the rates. Including the amortization of the upfront payments, our effective interest rate as of June 30, 2025, was 5.5%.

The below table summarizes our change in cash, cash equivalents, and restricted cash.


Table MD&A 10: Net Change in Cash and Cash Equivalents and Restricted Cash
	For the Nine Months Ended
	June 30, 2025		June 30, 2024
	(in thousands)
Operating activities:
Net cash (used in)/provided by operating activities	$	(220,000)	$	351,424
Net cash used in investing activities	(57,115)		(97,165)
Net cash provided by/(used in) financing activities	146,793		(229,819)
Effect of foreign exchange rates on cash and cash equivalents and restricted cash	(65)		1,270
Net change in cash and cash equivalents and restricted cash	$	(130,387)	$	25,710

Net Cash (Used in)/Provided by Operating Activities

We reported net cash used in operations of $220.0 million for the first nine months of fiscal year 2025, compared to net cash provided by operations of $351.4 million for the nine months of fiscal year 2024.

Through fiscal year 2025, we have experienced delays in cash collections from two of our larger customers.

Within our U.S. Federal Services Segment, we have experienced significant administrative delays in cash collections on one of our large programs, resulting in reduced cash inflows. Since June 30, 2025, we have made progress in resolving these issues and collected over $300 million of past-due receivables.

Table of Contents

Within our U.S. Services Segment, we have experienced delays related to a pending contractual extension of our work on a large state-based program. This extension was executed in July, and we have subsequently billed approximately $224 million, which had previously been held as unbilled receivables.

These delays are reflected in Days Sales Outstanding ("DSO") at June 30, 2025, which were 96 days, compared with 61 days at September 30, 2024. Excluding the effects of the RPA, DSO would have been 106 days and 65 days, respectively.

As a result of the resolution of these two matters, we anticipate that we will receive a significant benefit to operating cash flows in the final quarter of the fiscal year.

Net Cash Used in Investing Activities

We reported net cash used in investing activities of $57.1 million for the first nine months of fiscal year 2025, compared to net cash used in investing activities of $97.2 million for the first nine months of fiscal year 2024.

We continue to make investments in our capital base, most notably in upgrading technology on our Federal MDE contracts, which was completed in the third quarter of fiscal year 2025.

Net Cash Provided by/(Used in) Financing Activities

We reported net cash provided by financing activities of $146.8 million for the first nine months of fiscal year 2025, compared to net cash used in financing activities of $229.8 million for the first nine months of fiscal year 2024.

We have utilized our credit facilities in fiscal year 2025 to cover the short-term delays in collections noted above. In addition, we have utilized $306.4 million to repurchase approximately 4.1 million of our common shares.

Credit Facilities

Our principal debt agreement is with JPMorgan Chase Bank N.A. (the "Credit Agreement"). At June 30, 2025, we owed $1.67 billion under the Credit Agreement, with access to approximately $440 million through a revolving credit facility. Our principal loans mature in May 2029 and May 2031, when the remaining balances must be renegotiated or repaid in full. As disclosed above, we expanded one of our term loans by $250 million in March 2025. The revolving facility also matures in May 2029. In addition, our term loans require quarterly mandatory repayments.

The Credit Agreement contains a number of covenants. Failure to meet these requirements would result in a need to renegotiate the agreement, seek a waiver, or a requirement to repay our outstanding debt in full. There are two financial covenants, both defined in the Credit Agreement:

•Our Consolidated Net Total Leverage Ratio means, for any twelve-month period, the ratio of our Funded Debt (as defined by the Credit Agreement), offset by up to $150 million of unrestricted cash (Consolidated Net Total Leverage), against our Consolidated EBITDA (as defined by the Credit Agreement). To comply with our Credit Agreement, this ratio cannot exceed 4.00:1.00 at the end of each quarter, with a step up to 4.50:1.00 under certain circumstances. This ratio also determines both our interest rate and the charge we pay on the unused component of our revolving credit facility, with the charge increasing as the Consolidated Net Total Leverage Ratio increases.

•Our Consolidated Net Interest Coverage Ratio means, for any twelve-month period, the ratio of our Consolidated EBITDA against our Consolidated Net Interest Expense, as defined by the Credit Agreement. To comply with our Credit Agreement, this ratio cannot be less than 3.00:1.00 at the end of each quarter.

Consolidated EBITDA also drives certain permissions within the Credit Agreement, such as the level of investment we are entitled to make without seeking additional approval from our lenders.

Our Credit Agreement defines Consolidated EBITDA, as well as other components of the calculations above. The definition of Consolidated EBITDA requires us to include adjustments not typically included within EBITDA, including unusual, non-recurring expenses, certain non-cash adjustments, the pro forma effects of acquisitions and disposals, and estimated synergies from acquisitions. As a result, Consolidated EBITDA as defined by the Credit Agreement may not be comparable to EBITDA or related or similarly titled measures presented by other companies.

We have summarized below the components of our two financial ratio calculations, including the components of Consolidated EBITDA as defined by the Credit Agreement which are included within our financial statements. At June 30, 2025, we were in compliance with all applicable covenants of our Credit Agreement. We do not believe that these covenants represent a significant restriction on our ability to operate our business or to pay our dividends.

Table of Contents


Table MD&A 11: Reconciliation of Net Income to Consolidated EBITDA as defined by our Credit Agreement
	For the Three Months Ended		For the Trailing Twelve Months Ended
	June 30, 2025		June 30, 2025
	(in thousands)
Net income	$	105,981	$	316,250
Adjustments:
Interest expense	22,657		81,659
Other expense/(income), net	48		(1,528)
Provision for income taxes	36,986		120,801
Amortization of intangibles	23,010		92,079
Stock compensation expense	10,749		38,069
Acquisition-related expenses	69		1,098

Divestiture-related charges	—		39,343

Depreciation and amortization of property, equipment, and capitalized software	9,607		37,313
Pro forma and other adjustments permitted by our Credit Agreement	7,282		46,145
Consolidated EBITDA (as defined by our Credit Agreement)	$	216,389	$	771,229


Table MD&A 12: Consolidated Net Total Leverage Ratio
	For the Trailing Twelve Months Ended
	June 30, 2025
	(in thousands, except ratio data)
Funded Debt (as defined by our Credit Agreement)	$	1,670,583
Cash and cash equivalents up to $150 million	59,777
Consolidated Net Total Leverage (as defined by our Credit Agreement)	$	1,610,806

Consolidated Net Total Leverage Ratio (as defined by our Credit Agreement)	2.09


Table MD&A 13: Consolidated Net Interest Coverage Ratio
	For the Trailing Twelve Months Ended
	June 30, 2025
	(in thousands, except ratio data)
Consolidated EBITDA (as defined by our Credit Agreement)	$	771,229

Interest expense	81,659
Components of other income/expense, net allowed in ratio calculation	1,956

Consolidated Net Interest Expense (as defined by our Credit Agreement)	$	83,615

Consolidated Net Interest Coverage Ratio (as defined by our Credit Agreement)	9.22

Table of Contents

Cash in Foreign Locations

We have no requirement to remit funds from our foreign locations to the United States. We will continue to explore opportunities to remit additional funds, taking into consideration the working capital requirements and relevant tax rules in each jurisdiction. When we are unable to remit funds back without incurring a penalty, we will consider these funds indefinitely reinvested until such time as these restrictions are changed. As a result, we do not record U.S. deferred income taxes on any funds held in foreign jurisdictions. We have not attempted to calculate our potential liability from any transfer of these funds, as any such transaction might include tax planning strategies that we have not fully explored. Accordingly, it is not possible to estimate the potential tax obligations if we were to remit all of our funds from foreign locations to the United States.

Free Cash Flow (Non-GAAP)


Table MD&A 14: Free Cash Flow (Non-GAAP)
	For the Nine Months Ended
	June 30, 2025		June 30, 2024
	(in thousands)
Net cash (used in)/provided by in operating activities	$	(220,000)	$	351,424
Purchases of property and equipment and capitalized software	(55,686)		(82,237)
Free cash flow (Non-GAAP)	$	(275,686)	$	269,187

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires us to make estimates, judgments, and assumptions that affect the amounts reported. Actual results could differ from those estimates. The 2024 Form 10-K, as filed with the SEC on November 21, 2024, includes a summary of critical accounting policies we believe are the most important to aid in understanding our financial results. There have been no changes to those critical accounting policies that have had a material impact on our reported amounts of assets, liabilities, revenues, or expenses during the nine months ended June 30, 2025.

Non-GAAP and Other Measures

We utilize non-GAAP measures where we believe it will assist users of our financial statements in understanding our business. The presentation of these measures is meant to complement, but not replace, other financial measures in this document. The presentation of non-GAAP numbers is not meant to be considered in isolation, nor as an alternative to revenue growth, net cash provided by operating activities, net income, or earnings per share as measures of performance or liquidity. These non-GAAP measures, as determined and presented by us, may not be comparable to related or similarly titled measures presented by other companies.

For the three months ended June 30, 2025, 11% of our revenue was generated outside the U.S. We believe that users of our financial statements want to understand the performance of our foreign operations using a methodology that excludes the effect of year-over-year exchange rate fluctuations. To calculate year-over-year currency movement, we determine the current fiscal year's results for all foreign businesses using the exchange rates in the prior fiscal year.

In recent years, we made a number of acquisitions and divestitures. We believe users of our financial statements want to evaluate the performance of our operations, excluding changes that have arisen due to businesses acquired or disposed of. We identify acquired revenue and cost of revenue by showing these results for periods for which no comparative results exist within our financial statements. We identify revenue and cost of revenue that has been disposed of in a similar manner. This information is supplemented by our calculations of organic growth. To calculate organic growth, we compare current fiscal year results, excluding transactions from acquisitions or disposals, to our prior fiscal year results.

Our previous acquisitions have resulted in significant intangible assets, which are amortized over their estimated useful lives. We believe users of our financial statements want to understand the performance of the business by using a methodology that excludes the amortization of our intangible assets. For the nine months ended June 30, 2025 and 2024, we also incurred losses on sales of businesses. We believe that providing supplemental measures that exclude the impact of the items detailed below is useful to investors in evaluating our core operations and results in relation to past periods. Adjusted EBITDA is also a useful measure of performance that focuses on the cash generating capacity of the business

Table of Contents

as it excludes the non-cash expenses of depreciation, amortization and divestiture-related charges, and makes for easier comparisons between the operating performance of companies with different capital structures by excluding interest expense and therefore, the impacts of financing costs. Accordingly, we have calculated our operating income, Adjusted EBITDA, net income, and diluted earnings per share, excluding the effect of the amortization of intangible assets and divestiture-related charges. As disclosed above, Adjusted EBITDA is calculated in a different manner from Consolidated EBITDA, as defined by our Credit Agreement. We have included a table showing our reconciliation of these income measures to their corresponding GAAP measures.


Table MD&A 15: Non-GAAP Adjusted Results - Operating Income, Adjusted EBITDA, Net Income, and Diluted Earnings per Share
	For the Three Months Ended						For the Nine Months Ended
	June 30, 2025			June 30, 2024			June 30, 2025			June 30, 2024
	(dollars in thousands, except per share data)
Operating income	$	165,672		$	141,739		$	405,427		$	376,743
Add back: Amortization of intangible assets	23,010			23,542			69,041			68,532
Add back: Divestiture-related charges	—			—			39,343			1,018



Add back: Depreciation and amortization of property, equipment, and capitalized software	9,607			7,530			27,502			24,146
Adjusted EBITDA (Non-GAAP)	$	198,289		$	172,811		$	541,313		$	470,439
Adjusted EBITDA margin (Non-GAAP)	14.7		%	13.1		%	13.2		%	11.8		%

Net income	$	105,981		$	89,752		$	243,746		$	234,410
Add back: Amortization of intangible assets, net of tax	16,958			17,350			50,883			50,508
Add back: Divestiture-related charges	—			—			39,343			1,018
Adjusted net income excluding amortization of intangible assets and divestiture-related charges (Non-GAAP)	$	122,939		$	107,102		$	333,972		$	285,936

Diluted earnings per share	$	1.86		$	1.46		$	4.20		$	3.81
Add back: Effect of amortization of intangible assets on diluted earnings per share	0.30			0.28			0.88			0.82
Add back: Effect of divestiture-related charges on diluted earnings per share	—			—			0.67			0.02
Adjusted diluted earnings per share excluding amortization of intangible assets and divestiture-related charges (Non-GAAP)	$	2.16		$	1.74		$	5.75		$	4.65

In order to sustain our cash flows from operations, we regularly refresh our fixed assets and technology. We believe that users of our financial statements want to understand the cash flows that directly correspond with our operations and the investments we must make in those operations using a methodology that combines operating cash flows and capital expenditures. We provide free cash flow to complement our statement of cash flows. Free cash flow shows the effects of our operations and replacement capital expenditures and excludes the cash flow effects of acquisitions, purchases of our common stock, dividend payments, and other financing transactions. We have provided a reconciliation of cash flows from operations to free cash flow in "Liquidity and Capital Resources."

To sustain our operations, our principal source of financing comes from receiving payments from our customers. We believe that users of our financial statements want to evaluate our efficiency in converting revenue into cash receipts. Accordingly, we provide DSO, which we calculate by dividing billed and unbilled receivable balances at the end of each quarter by revenue per day for the quarter. Revenue per day for a quarter is determined by dividing total revenue by 91 days.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

In the normal course of business, we are exposed to financial risks such as changes in interest rates, foreign currency exchange rates, and counterparty risk. We use derivative instruments to manage selected interest rate exposures. The Company's market rate risk disclosures set forth in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" on the 2024 Form 10-K, have not changed materially during the nine month period ended June 30, 2025.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective and designed to ensure that the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified by the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II - Other Information

Item 1. Legal Proceedings

Refer to our disclosures included in "Note 11. Commitments and Contingencies" included in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors

In connection with the information set forth in this Form 10-Q, the risk factors under Part I, Item 1A "Risk Factors" in our 2024 Form 10-K, as supplemented by the risk factor set forth in Part II, Item 1A "Risk Factors" in our 2025 Q2 Form 10-Q, should be considered. The risks included in the 2024 Form 10-K as supplemented by the risks in the 2025 Q2 Form 10-Q could materially and adversely affect our business, financial condition and results of operations. There were no material changes during the three month period ended June 30, 2025 to the risk factors discussed in the 2024 Form 10-K, as supplemented by the risk factor in the 2025 Q2 Form 10-Q.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a)None.

(b)None.

(c)None.

Item 3. Defaults Upon Senior Securities

(a)None.

(b)None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

(a)None.

(b)None.

(c)During the three months ended June 30, 2025, no director or officer of the Company adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Table of Contents

Item 6. Exhibits

Exhibit
No.

Description of Exhibit

3.1

Amended and Restated By-laws of the Company, effective June 10, 2025 (incorporated by reference to the Company's Current Report on Form 8-K, filed June 12, 2025).

31.1

Certification of Chief Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002.

32.1

Certification of Chief Executive Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002.

32.2

Certification of Chief Financial Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance Document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

101.CAL

Inline XBRL Taxonomy Calculation Linkbase Document.

101.DEF

Inline XBRL Taxonomy Definition Linkbase Document.

101.LAB

Inline XBRL Taxonomy Label Linkbase Document.

101.PRE

Inline XBRL Taxonomy Presentation Linkbase Document.

104

Cover Page Interactive Data File (formatted as Inline XBRL tags and contained in Exhibit 101).



v			Filed herewith.
Φ			Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Maximus, Inc.

	/s/ Bruce L. Caswell	August 7, 2025
By:	Bruce L. Caswell
	President and Chief Executive Officer
	(Principal Executive Officer)

	/s/ David W. Mutryn	August 7, 2025
By:	David W. Mutryn
	Chief Financial Officer
	(Principal Financial Officer)

MAXIMUS, INC. 10-Q